Cargando…

Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer

BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Jessica, Ozden, Ozkan, Akagi, Naomi, Carroll, Timothy, Principe, Daniel R., Staudacher, Jonas J., Spehlmann, Martina E., Eckmann, Lars, Grippo, Paul J., Jung, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619565/
https://www.ncbi.nlm.nih.gov/pubmed/26497569
http://dx.doi.org/10.1186/s12943-015-0456-4
_version_ 1782397132128387072
author Bauer, Jessica
Ozden, Ozkan
Akagi, Naomi
Carroll, Timothy
Principe, Daniel R.
Staudacher, Jonas J.
Spehlmann, Martina E.
Eckmann, Lars
Grippo, Paul J.
Jung, Barbara
author_facet Bauer, Jessica
Ozden, Ozkan
Akagi, Naomi
Carroll, Timothy
Principe, Daniel R.
Staudacher, Jonas J.
Spehlmann, Martina E.
Eckmann, Lars
Grippo, Paul J.
Jung, Barbara
author_sort Bauer, Jessica
collection PubMed
description BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. METHOD: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) −/− or wild type mice. Colon cancer cell lines (+/− SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays. RESULTS: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling. CONCLUSION: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0456-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4619565
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46195652015-10-26 Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer Bauer, Jessica Ozden, Ozkan Akagi, Naomi Carroll, Timothy Principe, Daniel R. Staudacher, Jonas J. Spehlmann, Martina E. Eckmann, Lars Grippo, Paul J. Jung, Barbara Mol Cancer Research BACKGROUND: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer. METHOD: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) −/− or wild type mice. Colon cancer cell lines (+/− SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays. RESULTS: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast, TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with activin-dependent PI3K signaling. CONCLUSION: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT. p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0456-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-24 /pmc/articles/PMC4619565/ /pubmed/26497569 http://dx.doi.org/10.1186/s12943-015-0456-4 Text en © Bauer et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bauer, Jessica
Ozden, Ozkan
Akagi, Naomi
Carroll, Timothy
Principe, Daniel R.
Staudacher, Jonas J.
Spehlmann, Martina E.
Eckmann, Lars
Grippo, Paul J.
Jung, Barbara
Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title_full Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title_fullStr Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title_full_unstemmed Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title_short Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer
title_sort activin and tgfβ use diverging mitogenic signaling in advanced colon cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619565/
https://www.ncbi.nlm.nih.gov/pubmed/26497569
http://dx.doi.org/10.1186/s12943-015-0456-4
work_keys_str_mv AT bauerjessica activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT ozdenozkan activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT akaginaomi activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT carrolltimothy activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT principedanielr activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT staudacherjonasj activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT spehlmannmartinae activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT eckmannlars activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT grippopaulj activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer
AT jungbarbara activinandtgfbusedivergingmitogenicsignalinginadvancedcoloncancer